SCHEMBL4720155

SCHEMBL4720155

CCCCOc1o[c]nc1-c1cccc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.39
HTR1B P28222 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 1/20 0.39
CNR2 P34972 3/20 0.38
CNR1 P21554 2/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
HTR1D P28221 1/20 0.37
TLR8 Q9NR97 1/20 0.37
ALOX15 P16050 4/20 0.37
CYP2C9 P11712 2/20 0.36
BCHE P06276 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
NPY1R P25929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720923 0.94 CNR1 (0.37) HTR1BGAACNR2CNR1CHRNB4
SCHEMBL4720960 0.88 ENPP1 (0.42) L3MBTL1GAACHRNB4CHRNA3CHRNA7
SCHEMBL4767199 0.81 BCHE (0.38) TDP1L3MBTL1ALOX15BCHEALDH1A1
SCHEMBL4723122 0.78 SOAT1 (0.42) GAACYP2C9BCHECYP1A2CYP19A1
SCHEMBL4720726 0.74 TLR8 (0.39) TDP1HTR1BL3MBTL1GAACNR2
SCHEMBL4765519 0.74 HTR1B (0.39) TDP1HTR1BL3MBTL1GAACNR2
SCHEMBL5097262 0.74 TLR8 (0.39) TDP1HTR1BL3MBTL1GAACNR2
SCHEMBL4723469 0.73 HTR1B (0.46) TDP1HTR1BL3MBTL1GAACNR2
SCHEMBL4724587 0.71 MAPT (0.37) GAAALDH1A1LMNA
SCHEMBL4720526 0.70 HTR1B (0.39) TDP1HTR1BL3MBTL1GAACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 TDP1 1332/4885HTR1B 111/4885L3MBTL1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.